This research compound is a cleavable drug-linker conjugate designed for constructing Antibody-Drug Conjugates (ADCs), specifically for coupling the potent topoisomerase I inhibitor Exatecan to an anti-HER3 antibody. It is utilized in preclinical in vitro and in vivo studies to investigate targeted cancer therapies, particularly against HER3-expressing tumors.